Key Takeaway: Precision BioSciences hosted a Virtual R&D Day to present new preclinical data related to its in vivo gene editing programs. The event emphasized the company's proprietary ARCUS technology and introduced PBGENE-PMM, a potential treatment for primary mitochondrial myopathy. Key opinion leaders participated in the event, discussing the advancements and future directions of the company's portfolio.
Price reaction · baseline $12.9 (2023-09-11 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
+2.3%
Market Sentiment Analysis
POSITIVE FACTORS
Showcases new preclinical data for gene editing programs.
Introduces PBGENE-PMM as a potential treatment for mitochondrial myopathy.
Highlights advancements in proprietary ARCUS technology.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Company highlights new preclinical data for wholly-owned and partnered programs following prioritization of in vivo gene editing portfolio – Expands portfolio with PBGENE-PMM as a potentially curative treatment for primary mitochondrial myopathy – Virtual R&D Day featuring key opinion leaders and
Frequently Asked Questions
What was highlighted during Precision BioSciences' R&D Day?
The event showcased new preclinical data and advancements in gene editing programs.
What is PBGENE-PMM?
PBGENE-PMM is a potentially curative treatment for primary mitochondrial myopathy.
Who participated in the Virtual R&D Day?
Key opinion leaders were featured during the Virtual R&D Day.
What technology does Precision BioSciences focus on?
The company emphasizes its proprietary ARCUS technology for gene editing.